8-K
filed May 8, 2025, 7:59 PM ET
ticker TERN
CIK 0001831363
earnings
confidence high
sentiment neutral
materiality 0.60
Terns Q1 net loss $23.9M; advances TERN-701 CML and TERN-601 obesity trials
Terns Pharmaceuticals, Inc.
2025-Q1 EPS
reported -$0.26
vs consensus -$0.29
▲ beat
(+9.0%)
- Net loss $23.9M ($0.26 EPS) vs $22.4M a year ago; R&D flat at $18.7M, G&A up to $8.7M.
- Cash, equivalents and marketable securities $334.3M at March 31, 2025; runway into 2028.
- Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 (CML); 6-month MMR data expected Q4 2025.
- Phase 2 FALCON trial of TERN-601 (obesity) enrolling; top-line 12-week weight loss data due Q4 2025.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0000950170-25-066952
- form_type
- 8-K
- ticker
- TERN
- cik
- 0001831363
- company_name
- Terns Pharmaceuticals, Inc.
- filed_at
- 2025-05-08T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:50.006165+00:00
- generated_at
- 2026-05-22T05:24:24.577523+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- earnings
- sentiment
- neutral
- materiality_score
- 0.6
- calibrated_materiality_score
- 0.6
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0000950170-25-066952
- json_url
- https://secwatch.observer/filing/0000950170-25-066952.json
- markdown_url
- https://secwatch.observer/filing/0000950170-25-066952.md
- text_url
- https://secwatch.observer/filing/0000950170-25-066952.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1831363/000095017025066952/0000950170-25-066952-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1831363/000095017025066952/tern-20250508.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
DAVEY TREE EXPERT CO
Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M
DAVEY TREE EXPERT CO
June 1, 2026, 1:50 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
BKE
Buckle Q1 net income $46.9M ($0.93/share), sales up 6.1% to $288.7M
BUCKLE INC
May 29, 2026, 3:38 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
HIND
Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis
Vyome Holdings, Inc
May 29, 2026, 8:42 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
PKE
Park Aerospace Q4 sales up 43% to $24.2M; EPS $0.19 vs $0.06 YoY; full-year net earnings double to $11.3M
PARK AEROSPACE CORP
May 28, 2026, 4:29 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
GAP
Gap Inc. Q1 net sales up 1% to $3.5B; adj. EPS $0.38; raises full-year EPS outlook
GAP INC
May 28, 2026, 4:16 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
PD
PagerDuty Q1 revenue $121M up 1% YoY; new CEO DiLullo; $100M buyback
PagerDuty, Inc.
May 28, 2026, 4:07 PM ET
earnings
Items 2.02, 8.01, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
RICK
RCI Hospitality posts Q2 GAAP loss of $0.04 on $7.6M impairment; non-GAAP EPS rises to $0.78
RCI HOSPITALITY HOLDINGS, INC.
May 28, 2026, 4:07 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
NTAP
NetApp reports Q4/FY2026 results (details not in filing) and adds $1B buyback
NetApp, Inc.
May 28, 2026, 4:05 PM ET
earnings
Items 2.02, 8.01, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.